The Impact of CAR T-Cell Therapy on Cancer Care

At the 2018 National Association of Specialty Pharmacy (NASP) Annual Meeting and Educational Conference, Cheryl Allen, BSPharm, MBA, Vice President of Industry Relations at Diplomat Pharmacy, discussed novel therapies in cancer care, including the emergence of CAR T-cell therapy as a groundbreaking oncology treatment.


You know, when we look at very novel therapies, the CAR T therapy is just fascinating. When we think about the ability to engineer a living cell to combat the patient’s cancer, it’s groundbreaking. What we see now in CAR T, and we’re looking at cancer therapy, we’re going to see that go all throughout different disease states and really begin to drilldown into precision therapy. 

Most Popular

Related Articles

A look at last week's top stories in the world of pharmacy.
Michael Reff, RPh, MBA, explains how the National Community Oncology Dispensing Association champions for best practices with the use of CDK4/6 (cyclin-dependent kinases 4 and 6) inhibitors for patients with breast cancer.
Study examines whether markers of biological aging due to cancer treatment are related to cognitive function in survivors of breast cancer.
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.